Cox regression analysis in the anti-PD-1 cohort revealed that only FBXL3, FBXO3, and PBRM1 mutation could serve as biomarkers of immunotherapy for patients with ccRCC (Figure 8C). This evidence concerns the gene FBXO3 and nonpapillary renal cell carcinoma.